Clinical Trial Update: A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Fruquintinib plus chemotherapy as postoperative treatment for HER2-negative gastric cancer with poor tumor regression grade; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING